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Abstract:  P-glycoprotein (P-gp), also known as  ABCB1, is a  member of  the  ABC 
transporter family of proteins. P-gp is an ATP-dependent drug efflux pump that is localized 
to the plasma membrane of mammalian cells and confers multidrug resistance in neoplastic 
cells. P-gp is a 140-kDa polypeptide that is glycosylated to a final molecular weight of  
170 kDa. Our experimental model used two variants of L1210 cells in which overexpression 
of P-gp was achieved: either by adaptation of parental cells (S) to vincristine (R) or by 
transfection with the human gene encoding P-gp (T). R and T cells were found to differ 
from S cells in transglycosylation reactions  in our recent studies.  The effects of 
tunicamycin on glycosylation, drug efflux activity and cellular localization of P-gp in R 
and T cells were examined in the present study. Treatment with tunicamycin caused less 
concentration-dependent cellular  damage  to  R and T cells  compared  with S cells. 
Tunicamycin inhibited P-gp N-glycosylation in both of the P-gp-positive cells. However, 
tunicamycin treatment did not alter  either the  P-gp cellular localization to  the  plasma 
membrane  or the P-gp  transport activity. The  present  paper brings evidence that 
independently on the mode of P-gp expression (selection with drugs or transfection with a 
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gene encoding P-gp) in L1210 cells, tunicamycin induces inhibition of N-glycosylation of 
this protein, without altering its function as plasma membrane drug efflux pump. 
Keywords: P-gp (MDR1); tunicamycin; N-glycosylation; L1210 
 
1. Introduction 
P-glycoprotein (P-gp),  also known as ABCB1, is a  member of the  ABC transporter family  of 
proteins, and it is an integral protein of the plasma membrane of animal cells [1]. When expressed in 
neoplastic tissue, P-gp represents a real obstacle for effective chemotherapy of neoplastic diseases, and 
tissues with increased P-gp are most often observed with the multidrug resistance (MDR) phenotype [2]. 
The known substrates of this protein represent a large group of unrelated substances,  including 
vincristine,  doxorubicin, mitomycin C, actinomycin D,  cyclophosphamide  and  dexamethasone  [3]. 
This protein encoded by the mdr1 (abcb1) gene is first synthesized as a 140-kDa polypeptide precursor 
that is later glycosylated to a final molecular weight of 170 kDa [4,5]. Each molecule of P-gp contains 
two nucleotide binding domains with the ABC consensus motif and two transmembrane domains that 
consist of six α-helical membrane spans [1].  
Glycosylation of P-gp  occurs on the  first  extracellular loop,  which contains  three putative 
glycosylation sites [6], and glycosylation of P-gp was not found to be necessary for the drug transport 
activity of P-gp. However, glycosylation of P-gp was shown to be important for proper quality control 
of P-gp in the endoplasmic reticulum [7] and proper transport of P-gp to the plasma membrane [6]. 
Tunicamycin is generally known to inhibit the process of protein N-glycosylation in the endoplasmic 
reticulum by blocking the transfer of N-acetylglucosamine-1-phosphate from uridine diphosphate-N-
acetyl-glucosamine to dolichol phosphate [8]. However, tunicamycin also induced an elevation of P-gp 
expression (at both the mRNA and protein levels) and efflux activity in Fao hepatoma cells [9]. This 
effect was due  to endoplasmic reticulum  stress and was  comparable  with  the  effects of other 
endoplasmic reticulum stress inducers, such as 2-deoxy glucose [10] and thapsigargin [11]. In contrast, 
tunicamycin-induced inhibition of total glycoprotein formation, including P-gp, was described for several 
cell models, and  inhibition of glycosylation conferred an increased sensitivity to different drugs [12]. 
Inhibition  of P-gp glycosylation by tunicamycin  was  associated  with  increased ubiquitination  and 
subsequent degradation of P-gp [13]. Thus, tunicamycin may induce either an increase or decrease in 
drug resistance associated with an improvement or impairment of P-gp function, respectively. This 
dual effect of tunicamycin seems to be due to differences between cell types. 
In the present study, we used two variants of L1210 cells that highly express P-gp. These variants 
were obtained from parental cells (S) either by stepwise adaptation to the drug vincristine (R) [14] or 
by stable transfection with the human gene encoding P-gp (T) [15]. The MDR phenotype of R cells 
was associated with an alteration in transglycosylation reactions linked with decreases in UDP-sugars, 
glycogen and cell surface sialic acid [16]. In addition, R cells differ from S cells in the composition of 
the cell surface saccharides that are ligands of concanavalin A and the tomato lectin Lycopersicum 
esculentum agglutinin [17]. While concanavalin A interacts more potently with S cells than with R 
cells, the tomato lectin exhibited the opposite behavior. Both lectins were shown to interact with Int. J. Mol. Sci. 2011, 12                       
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glycosylated proteins  in  the  plasma membrane other than  P-gp  [17].  The weak interaction of 
concanavalin A with P-gp-positive cells is directly related to presence of P-gp in L1210 cells because 
T cells displayed a similarly reduced interaction compared to S cells [15]. In addition, concanavalin A 
induced less cell death in R and T cells than in S cells. Therefore, both P-gp-positive L1210 cell 
variants are also cross-resistant to concanavalin A-induced cell death. Resistance to concanavalin A 
was found to be due to a defect in the overall biosynthesis of glycoproteins [18]. Alterations in the 
transglycosylation reaction and consequently in glycoprotein processing were  also  shown  in  the  
P-gp-positive L1210 cell variants [15–17]. Therefore, in the present study, we examined the effect of 
tunicamycin on P-gp glycosylation, membrane localization and transport activity. 
2. Results and Discussion  
2.1. P-gp Expression and Transport Activity in P-gp-Positive L1210 Cell Variants 
Both P-gp-positive L1210 cell variants (R and T cells) expressed large amounts of mRNA encoding 
P-gp  (Figure 1a), whereas  this  transcript  was barely detectable  in S cells. P-gp  protein  is  also 
detectable in R and T cells, but not in S cells using western blotting with the anti-P-gp antibody c219 
(Figure 1b). Western blotting showed a P-gp band with a molecular weight of 170 kDa in R and T cells 
that indicated a  fully  glycosylated form [5,7].  Several fluorescent substances are  known to be 
substrates of P-gp and are often used for detection of P-gp transport function directly in intact cells [1]. 
Calcein/AM, an intracellular calcium indicator, in the esterified form represents a suitable substrate for 
P-gp, but after intracellular deesterification, it is no longer transportable by P-gp [19,20]. The efflux 
activity of P-gp protects R and T cells against retention of calcein, while S cells were considerably 
loaded by this indicator (Figure 2). Verapamil, a blocker of the L-type calcium channel, is also known 
to be a potent inhibitor of P-gp [21]. This substance is able to block P-gp in R and T cells and allowed 
loading of these cells by calcein (Figure 2). A similar effect as verapamil could be achieved by the 
application of cyclosporine A (data not shown), which is known to be another potent inhibitor of P-gp [21]. 
Thus, overexpression of P-gp in both R and T cells at the levels of mRNA and protein conferred 
functional efflux activity. This confers strong resistance of R and T cells to P-gp substrates such  
as vincristine.  
2.2. The Effect of Tunicamycin on the Viability and Proliferation of S, R and T Cells 
Both of the P-gp-positive L1210 cell variants are slightly less sensitive to tunicamycin than the 
parental S cells. Tunicamycin in the range of 0.01–10.00 μmol/L induced concentration-dependent 
depression of proliferation that could be monitored by the MTT assay (Figure 3). While proliferation 
of S cells is blocked to 30% of the value of the untreated control at the highest applied tunicamycin 
concentration, more than 50% of R and T cells were viable under the same condition. 
The lower sensitivity of the P-gp-positive L1210 cell variants to tunicamycin could be directly 
related to P-gp expression because is independent of the method of P-gp expression (i.e., adaptation to 
vincristine or transfection with the human gene encoding P-gp). However, the decrease in tunicamycin 
sensitivity of the P-gp-positive R and T cells is unrelated to P-gp transport activity because verapamil, Int. J. Mol. Sci. 2011, 12                       
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a potent inhibitor of this activity, induced only non-significant effects  on  the viability of   
tunicamycin-treated R and T cells (Figure 3). 
Figure 1. (a) Detection of mRNA encoding P-gp using reverse transcription polymerase 
chain reaction. PCR products obtained from total mRNA isolation from S, R and T cells by 
reverse transcription and PCR amplification with P-gp-specific primers were subjected to 
agarose gel electrophoresis (St represents molecular weight standards). PCR products of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as an internal standard. 
(b) Western blot and Galanthus nivalis agglutinin (GNA) lectin blot analysis for detection 
of P-gp. Western blotting for GAPDH was used as an internal control for protein loading. 
The cells were three passages  cultivated in the absence or presence of 0.1 μmol/L 
tunicamycin. These data are representative of three independent measurements. 
 
Figure  2.  Detection of P-gp function by calcium retention assay in FACS. Data are 
representative of three independent measurements.  
 
   
100 101 102 103 104 100 101 102 103 104
80
40
0
80
40
0
80
40
0
C
o
u
n
t
s
Calcein fluorescence intensity
0 µmol/l  verapamile                       10 µmol/l verapamile
S
R
TInt. J. Mol. Sci. 2011, 12                       
 
 
7776 
Figure 3. The effect of tunicamycin on the viability of S, R and T cells. Data represent the 
mean ± SD of six independent measurements. The a indicates a statistically significant 
difference from the corresponding value obtained for S cells with p < 0.01.  
 
The main difference between the P-gp-negative S cells and the P-gp-positive R and T cells was 
obtained by repeated cultivation of cells in the presence of 0.1 μmol/L tunicamycin. While R and T 
cells showed no growth effect in response to repeated cultivation in treatment medium, S cells failed to 
grow after the third passage of cultivation (Supplementary Figure Ia). The viability of R and T cells 
after repeated cultivations with tunicamycin measured by fluorescein diacetate and propidium iodide 
was not altered (Supplementary Figure Ib). The decrease of fluorescein diacetate labeling was visible 
in S cells after the third passage of cultivation in the presence of tunicamycin. The anti-proliferative 
effect of tunicamycin on L1210 cells was associated with a decrease in the incorporation of sugar 
moieties onto cellular glycoproteins [22]. Morin and colleagues found that the treatment of cells with 
tunicamycin resulted in an increase of intracellular pool of UDP-N-acetylglucosamine that was 
associated with distentions of the endoplasmic reticulum and the nuclear membranes.  Similar 
ultrastructural changes and increases in the intracellular pools of UDP-sugars were observed in L1210 
cells exposed to 5 mmol/L  D-glucosamine, which suggests that the antiproliferative effects of 
tunicamycin may be related to the accumulation of one or more of the nucleotide-sugar precursors of 
asparagine-linked glycoprotein biosynthesis in the endoplasmic reticulum [22]. We have previously 
described a strong decrease of UDP-sugars in P-gp-positive L1210 cells [16]. Therefore, the resistance 
of P-gp-positive L1210 cells to tunicamycin may be due to the decreased levels of UDP-sugars in  
these cells. 
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2.3 The Effect of Tunicamycin on Glycosylation and Membrane Localization of P-gp. 
P-gp could be detected in crude membrane fractions using western blotting as a 170-kDa protein 
band, which indicated a fully glycosylated mature glycoprotein (Figure 1b). When R and T cells were 
repeatedly cultivated in the presence of tunicamycin, P-gp was detected using western blotting with the 
same antibody as 150-kDa protein bands, suggesting that the protein was  non-glycosylated. This is 
shown in Figure 1b after three passages of repeated cultivation in the presence of tunicamycin. Similar 
results  were  obtained when cells were cultivated in the presence of tunicamycin for  one, six or  
twenty-four passages of cultivation (the presence of non-glycosylated P-gp in R and T cells after  
24 passages is documented  in Supplementary Figure II).  We have previously observed the same  
150-kDa non-glycosylated P-gp when thapsigargin, another inducer of endoplasmic reticulum stress, 
was applied [23]. The sugar chains attached to P-gp were recently found to interact with Galanthus 
nivalis agglutinin (GNA) and Sambucus nigra agglutinin (SNA) [4]. Crude membranes isolated from 
R and T cells contained a protein band of 170 kDa that could be stained by GNA using a lectin blot 
(Figure 1b). There was no protein band observed using lectin blot with GNA in the crude membrane 
fraction isolated from S cells. The protein bands detected using the GNA-specific lectin blot in R and 
T cells were diminished when these cells were treated with tunicamycin. In another set of experiments, 
we observed similar results using an SNA-specific lectin blot (data not shown). Taken together, these 
results illustrate that tunicamycin potently inhibited P-gp glycosylation because only non-glycosylated 
P-gp is present in both P-gp-positive cell variants after treatment with this antibiotic. Because we were 
using crude membrane preparations  that include all cell membrane structures  in this western blot 
analysis, the localization of the non-glycosylated P-gp after treatment with tunicamycin was unknown. 
Therefore,  we  examined the cellular localization of P-gp after tunicamycin treatment using 
immunofluorescence confocal microscopy with the c219 anti-P-gp antibody and a FITC-conjugated 
anti-mouse secondary antibody. Both P-gp-positive variants of L1210 cells showed the P-gp protein 
localized to the surface structures of the cells. In contrast, P-gp could not be detected in S cells, similar 
to our results from western blot analysis. After R and T cells had been cultivated in the presence of 
tunicamycin  for three passages,  which resulted in the  non-glycosylated 150-kDa  form of P-gp  
(Figure 1b), the localization of P-gp was still detected on surface structures of the cells, similar to 
untreated cells (Figure 4). Similar results were obtained when cells were cultivated in the presence of 
tunicamycin  for  one, six or  twenty-four  passages  (data  not shown). Thus, the  prevention of P-gp  
N-glycosylation by tunicamycin did not alter its cell localization. 
The inhibition of N-glycosylation by tunicamycin was shown to induce an increase in P-gp 
ubiquitination and proteasomal degradation in a P-gp-positive MCF7 cell variant [13]. Consistent with 
this finding, treatment with tunicamycin caused a reduction of the P-gp-mediated MDR phenotype [24]. 
Degradation by the proteasome represents the final step for incorrectly synthesized proteins, including 
P-gp, during quality control in endoplasmic reticulum [7]. However, the application of tunicamycin to 
human MDR KB-C1 cells induced a hypersensitivity to 2-deoxyglucose due to an alteration of the 
function of the glucose transporter GLUT1, which did not  influence  P-gp transport activity [25]. 
Therefore, in some cases after treatment with tunicamycin, non-glycosylated P-gp could escape from 
the proteasomal degradation pathway. Both P-gp-positive L1210 cell variants used in the current study 
represent examples of the latter behavior. Int. J. Mol. Sci. 2011, 12                       
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Figure 4. (a) Visualization by immunofluorescence confocal microscopy of the localization 
of P-gp in cells cultivated for three passages in the absence or presence of tunicamycin. 
Nuclei were stained using 4',6-diamidino-2-phenylindole (blue). P-gp was detected using 
the  c219 anti-P-gp antibody and a  FITC-conjugated  anti-mouse  secondary  antibody 
(green). In the negative control, the c219 antibody was omitted, and the cells were incubated 
with a FITC-conjugated anti-mouse secondary antibody alone. These data are representative 
of  three independent measurements.  (b)  Cells from the same experiments in (a)  at  a  
higher magnification. 
 
2.4. Effect of Tunicamycin on P-gp Transport Activity 
As previously described above, R and T cells could be repeatedly cultivated in the presence of  
0.1 μmol/L tunicamycin. In contrast, S cells stopped proliferating after the third passage of cultivation 
in this condition. Therefore, we used S cells cultivated in the absence or presence of a single passage 
of tunicamycin treatment in a calcein retention assay. The R and T cells used in the calcein retention 
assay  were  cultivated in the absence or presence of one, three, six or  twenty-four  passages  of 
tunicamycin treatment. S cells exhibited retention of calcein independent of the presence or absence of 
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tunicamycin (Figure 5). In contrast, the retention of calcein was reduced in R and T cells due to the 
overexpression of P-gp, and the efflux activity of P-gp was not affected by the presence of tunicamycin 
during repeating cultivation. Therefore, after tunicamycin treatment, the  non-glycosylated P-gp  
(Figure 1b) that is incorporated into the plasma membrane (Figure 4) retains the ability to transport 
calcein out of the cell (Figure 5). Calcein could be retained in R and T cells treated repeatedly with 
tunicamycin by verapamil (as demonstrated in cells after 24 passages in medium with tunicamycin in 
Supplementary Figure III). This finding demonstrates that P-gp transport function was not altered in 
the R and T cells by the inhibition of N-glycosylation after tunicamycin treatment. Thus, sufficient 
levels  of P-gp  are accurately incorporated into the plasma membrane  to  fully develop  the  MDR 
phenotype in the R and T cells treated with tunicamycin, even though the N-glycosylation of P-gp is 
strongly inhibited by this treatment. Consistent with this hypothesis, tunicamycin treatment of R and T 
cells failed to alter the resistance to vincristine, another known P-gp substrate (Supplementary Figure 
III). This resistance to vincristine could be reversed by verapamil. In P-gp-negative HL60/AR cells, the 
MDR phenotype was found to be due to hypoglycosylated membrane proteins [26]. A similar pattern 
of  hypoglycosylated membrane glycoproteins  was  observed in drug-sensitive HL60 cells after 
treatment with tunicamycin, and this antibiotic altered the drug sensitivity of the treated HL60 cells. 
The question of whether tunicamycin caused any additional alteration of the drug sensitivity in R  
and T cells due to hypoglycosylated membrane proteins other than P-gp would be of interest for  
future studies. 
Figure 5. Calcein/AM retention assay of the influence of tunicamycin on P-gp transport 
function. Cells (S, R and T) were cultivated in the absence (tun0) or the presence of one 
(tun1), three (tun3), six (tun6) or twenty-four passages (tun24) of 0.1 μmol/L tunicamycin 
treatment, and then the calcium/AM assay was performed. These data are representative of 
three independent measurements. 
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3. Experimental Section 
3.1. Cell Culture Conditions 
The following three L1210 cell variants were used in this study: (i) S—drug-sensitive parental cells; 
(ii) R—P-gp-positive drug-resistant cells that overexpress P-gp after selection with vincristine (VCR, 
from Gedeon Richter Co., Hungary) [14]; and (iii) T—P-gp-positive drug-resistant cells that 
overexpress P-gp following stable transfection with the P-gp gene [15] using the Addgene plasmid 
10957 (pHaMDRwt), a retrovirus encoding the full-length P-gp cDNA [27]. The cells (S, R and T; 
inoculums 1 × 10
6 cells) were cultured in 4 mL RPMI 1640 media with L-glutamine (1 mg/mL), 4% 
fetal  bovine  serum  and  1  μg/mL  gentamycin (all purchased from Gibco, USA) in a humidified 
atmosphere with 5% CO2 and air at 37 °C for 48 h in the absence or presence (0.01–10 μmol/L) of 
tunicamycin. This procedure was termed as passage. R cells were cultured for two passages without 
VCR prior to the experiments. 
3.2. Detection of the P-gp mRNA 
The total mRNA was extracted from S, R and T cells using the RNA-solvent reagent concentrate 
R6830-02IN (OMEGA Bio-Tek, USA). mRNA was reverse-transcribed to cDNA using a First Strand 
cDNA Synthesis Kit (Novagen, USA). Both mRNA extraction and cDNA synthesis were carried out 
according to protocols recommended by Novagen. PCR reactions were performed using the Nova Taq 
PCR Master Mix (Novagen, USA). The following PCR primers were used: the mdr1 gene, 5'-CCC 
ATC ATT GCA ATA GCA GG-3' and 5'-GTT CAA ACT TCT GCT CCT GA-3', which yielded a 
167-bp product, and the gapdh gene as an internal control, 5'-TAT GTC GTG GAG TCT ACT GGT 
GTC-3' and 5'-GTC ATC ATA CTT GGC AGG TTT CTC-3', which yielded a 453-bp product. PCR 
reactions were carried out using 30 cycles of a 1 min denaturation step at 94 °C, a 1 min annealing step 
at 57 °C (for GAPDH) or at 55 °C (for mdr1), and a 2 min extension step at 72 °C according to the 
protocol recommended by Novagen. The  PCR products were separated using  a 1.7% agarose gel 
(Invitrogen) and visualized using ethidium bromide with a Typhoon 9210 imager (GE Healthcare, 
USA, formerly Amersham Biosciences). 
3.3. Examination of P-gp Function Using Calcein/AM Assay 
After cultivation, S, R and T cells (5 × 10
5) were washed twice in PBS containing 0.1% bovine 
serum albumin and were then resuspended in 500 μL of the same buffer. Calcein/AM (Sigma-Aldrich, 
final concentration of 0.1 μmol/L) and propidium iodide (final concentration of 0.9 μmol/L) were 
added directly to the buffer, and the samples were incubated for 20 min at 37 °C. After incubation, the 
cells were washed twice in ice cold PBS. Fluorescence was measured using the Coulter Epics Altra 
flow cytometer (USA) 
3.4. The Effect of Tunicamycin on S, R and T Cell Proliferation 
Cells (5 × 10
4 cells in each well) were cultured either with or without tunicamycin (concentration 
range 0.01–10 μmol/L) and verapamil (10  μmol/L) in 96-well culture plates. Verapamil and tunicamycin Int. J. Mol. Sci. 2011, 12                       
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(obtained from Sigma Aldrich USA) were added directly to the culture media. After 48 h, cell viability 
was assayed using the MTT test [28], which was performed by adding MTT ([3-(4,5-dimethyldiazol-2-
yl)-2,5 diphenyl tetrazolium bromide]) at a final concentration of 0.25 mg/mL to each well. The cells 
were incubated with MTT for 2 h. Then the plates were centrifuged for 15 min (2500 rpm), and the cell 
sediment was extracted using dimethyl sulfoxide. The absorbance at 540 nm was measured using a 
Universal Microplate Spectrophotometer mQuant (BioTek Instruments, Inc. USA). Statistical 
significance was analyzed using the unpaired Student’s t-test. 
3.5. Examination of the Effect of Tunicamycin on P-gp Levels in S, R and T Cells Using Western Blot 
and GNA Blot Analysis 
After incubation, the cells were harvested, and crude membrane fractions were prepared with a 
ProteomeExtract Subcellular Proteome Extraction Kit (Calbiochem) according to the manufacturer’s 
instructions. Proteins from the samples were separated by sodium dodecyl sulfate polyacrylamide 
electrophoresis (SDS-PAGE) using 8% polyacrylamide gels [29]. Proteins were then transferred by 
electroblotting to a nitrocellulose membrane [30]. P-gp was detected using the c219 anti-P-gp 
monoclonal antibody (Calbiochem, USA). A secondary anti-mouse antibody conjugated with 
horseradish peroxidase (GE Healthcare, USA) was used for detection. To provide an internal control 
for protein loading, rabbit polyclonal antibodies against GAPDH (Santa Cruz Biotechnology, USA), 
were used as primary antibodies, and goat anti-rabbit IgG conjugated with horseradish peroxidase 
(Santa Cruz Biotechnology, USA) served as a secondary antibody. Protein bands were visualized using 
the ECL detection system (GE Healthcare) and the Kodak (USA) CF 440 imaging system. For GNA-specific 
lectin  blots,  proteins were visualized with methods similar  to  those for  western blotting, using a 
biotinylated-GNA and streptavidin conjugated with peroxidase (Sigma-Aldrich USA). 
3.6. Visualization of the P-gp in S, R and T Cells Using Immunofluorescence Confocal Microscopy 
After cultivation, the cells were washed and resuspended in PBS, and then the cells were transferred 
onto poly-L-lysine cover glasses (Menzel Glaser, Germany). The bound cells were washed twice in 
PBS and then fixed with methanol at −20 °C for 20 min after fixation, the cells were washed in PBS 
and then blocked by incubation with 1% BSA in PBS for 1 h at 37 °C. Next, the cells were incubated 
with the c219 anti-P-gp antibody for 1 h at 37 °C in PBS containing 1% BSA. After the primary 
antibody incubation, the cells were washed twice in PBS containing 1% BSA. Then the cells were 
incubated with FITC-conjugated goat anti-mouse antibody (Calbiochem, USA) in PBS containing 1% 
BSA for 1 h at 37 °C and then washed twice in PBS containing 1% BSA. The immunofluorescently 
labeled cells were also labeled with 10 mg/L of 4'-6-diamidino-2-phenylindole (DAPI, Sigma USA) in 
PBS to visualize the nuclei [31]. Finally, the coverslips were mounted onto slides with a mounting 
medium (80% glycerol) and analyzed using a confocal laser scanning microscope (LSM 510 META 
Carl Zeiss). 
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4. Conclusions 
Tunicamycin effectively blocked N-glycosylation of P-gp in both of the P-gp-positive cell variants 
of L1210 cells analyzed (R and T cells) because only the non-glycosylated 150 kDa P-gp could be 
detected using western blotting after cultivation in the presence of 0.1 μmol/L of this antibiotic. In 
addition, the P-gp in tunicamycin-treated R and T cells was undetectable using a GNA-specific lectin 
blot. However, inhibition of N-glycosylation of P-gp did not alter its plasma membrane localization or 
drug efflux activity.  Thus it could be stated that independently on the mode of P-gp expression 
(selection with drugs or transfection with gene encoding P-gp) in L1210 cells, tunicamycin induces 
inhibition of N-glycosylation of this protein without altering its function as plasma membrane drug 
efflux pump. 
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